Abstract: The present invention relates to a drop-forming, storage stable, multiphase, ophthalmic composition comprising at least one liquid aqueous phase and at least one liquid hydrophobic phase, characterized in that it is emulsifier-free as well as buffer-free and comprises hyaluronic acid and/or hyaluronate.

Abstract: The present invention relates to a drop-forming, storage stable, multiphase, ophthalmic composition comprising at least one liquid aqueous phase and at least one liquid hydrophobic phase, characterized in that it is emulsifier-free as well as buffer-free and comprises hyaluronic acid and/or hyaluronate.

Abstract: The present invention relates to a method for coating a surface of a substrate with a drug for sustained release: (i) providing a substrate with a surface to be coated, (ii) depositing at least one bilayer on at least a portion of said surface, wherein one layer of the bilayer comprises a polyelectrolyte and the other layer comprises a pharmaceutically active ingredient, and wherein the two layers of the bilayer are oppositely charged under conditions of the deposition and one layer of the bilayer has a substantially different net charge under physiological conditions. The invention also pertains to substrates with microscopic or macroscopic surfaces coated with the method according to the invention.

Abstract: The present invention relates to drug formulations for the stabilization of amorphous forms of drugs. In particular the present invention relates to pharmaceutical compositions comprising sponge-like carrier matrices, particularly polyelectrolyte complexes or porous particles. The invention also relates to methods for the production of such pharmaceutical compositions.

Abstract: A method for making an article comprising a core material and a coating thereon, the method comprising the steps of: (a) providing the core material; (b) applying one or more layers of a crosslinkable polycationic material, wherein the polycationic material is a reaction product of: (i) an epoxide of formula (I) wherein X equals bromo, chloro, iodo, or cyano, and R1, R2, R3, R4, independently of one another, are selected from the group consisting of hydrogen, linear or branched C1-C6-alkyl, and linear or branched C1-C6-alkyl which is substituted with halogen, and (ii) a polymer having repeating units comprising one or more secondary or tertiary amine group(s); (c) applying one or more layers of a polyanionic material; and (d) cross-linking the layers of polyelectrolytes formed by steps (b) and (c).

Abstract: A drug-releasing polyelectrolyte coating includes: (a) at least two oppositely charged polyelectrolyte layers; (b) at least one pharmaceutical active drug which is covalently coupled to polyelectrolytes of at least one of the polyelectrolyte layers; (c) wherein the drug exhibits a release rate from the polyelectrolyte coating of less than 50% in 3 days.

Abstract: A method for making an article comprising a core material and a coating thereon, the method comprising the steps of: (a) providing the core material; (b) applying one or more layers of a crosslinkable polycationic material, wherein the polycationic material is a reaction product of: (i) an epoxide of formula (I) wherein X equals bromo, chloro, iodo, or cyano, and R1, R2, R3, R4, independently of one another, are selected from the group consisting of hydrogen, linear or branched C1-C6-alkyl, and linear or branched C1-C6-alkyl which is substituted with halogen, and (ii) a polymer having repeating units comprising one or more secondary or tertiary amine group(s); (c) applying one or more layers of a polyanionic material; and (d) cross-linking the layers of polyelectrolytes formed by steps (b) and (c).

Abstract: The present invention is concerned with solid, single-dose dosage forms for an increased rate of release of slightly soluble active ingredients. The dosage forms are based on a coherent matrix which disintegrates rapidly in physiological fluids. The matrix comprises one or more slightly soluble active ingredients in the form of fast-release micro- or nanocapsules. The dosage form is particularly suitable for administering those slightly soluble active ingredients for which a rapid onset of action is desired.